StockData
Belite Bio, Inc logo

Belite Bio, Inc (BLTE) stock

BLTENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026Score 5/30
$157.72−4.84 (-2.98%)

Close on Nov 17, 2026Market cap $6.20BP/E –Yield –

Belite Bio r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was $45.38M, up 51.6% from the year before. The highest annual figure on record is $45.38M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$45.38M+51.6%
FY2024Dec 31, 2024$29.94M+20.5%
FY2023Dec 31, 2023$24.84M+180.1%
FY2022Dec 31, 2022$8.87M+19.5%
FY2021Dec 31, 2021$7.42M+101.2%
FY2020Dec 31, 2020$3.69M–

More Belite Bio figures

See a number that looks wrong?